Skip to main content

Table 3 Induction treatment response (n = 107)

From: Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

Treatment response N (%)
Complete response (CR) 2 (1.9)
Very good partial response (VGPR) 40 (37.4)
Partial response (PR) 46 (43)
Mixed response (MR) 19 (17.8)
No response (NR)
Progressive disease (PD)
  1. Notes: Data are presented as number (%) for categorical variables